R. Medori

Publications100
h-index36
Citations5,496
Highly Influential Citations191
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Bézard
  • 406 Publications • 23,666 Citations
  • J. Kane
  • 1,064 Publications • 57,623 Citations
  • J. Biederman
  • 1,146 Publications • 121,062 Citations
  • L. Greenhill
  • 290 Publications • 34,482 Citations
  • Publications
  • Influence
Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei.
TLDR
The thalamus is affected in diffuse degenerative processes of the nervous system and it has not been established whether a genetically determined degenerative disease may be limited in patients with this organ.
View on PubMed
Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.
TLDR
These data show the clinical consequences of both quantitative alterations (in Duchenne's and intermediate dystrophy) in a single protein, and the biochemical assay for dystrophin should prove helpful in delineating myopathies that overlap clinically with DuchenNE's and Becker's Dystrophies and shows promise as an accurate diagnostic tool.
View on PubMed
Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene.
TLDR
Fatal familial insomnia is a prion disease with a mutation in codon 178 of the PrP gene, but the disease phenotype seems to differ from that of previously described kindreds with the same point mutation.
View on PubMed
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
View on Elsevier
Time course for antipsychotic treatment response in first-episode schizophrenia.
TLDR
Time to antipsychotic response varied widely, suggesting that, in first-episode schizophrenia, longer treatment trials may be necessary.
View on PubMed
A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder
View on Elsevier
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection
TLDR
The results of this open-label study suggest that a majority of first-episode patients who receive long-acting injectable antipsychotic medication may achieve sustained remission.
View on Wolters Kluwer
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
View on PubMed
Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
TLDR
RLAI provides an advancement in the treatment options available for a wide range of patients requiring long-term antipsychotic therapy and patient satisfaction with treatment, and scores on ESRS showed significant, sustained improvements throughout the study period.
View on Wolters Kluwer
Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis: A Preliminary Study
TLDR
This preliminary study suggests that RLAI was overall well tolerated and appears to be effective in recent-onset psychosis.
View on Wolters Kluwer
...
...